DEF: Stryker Corporation Announces Details for 2025 Annual Shareholder Meeting, Including Director Elections and Incentive Plan Approvals

Stryker Corporation's upcoming annual shareholder meeting on May 8, 2025, will address key items including director elections, ratification of the accounting firm, and approval of incentive plans.

Summary

• Stryker Corporation will hold its annual shareholder meeting virtually on May 8, 2025, at 9:30 a.m. Eastern Time.
• Shareholders of record as of March 10, 2025, are eligible to vote on several proposals.
• The proposals include the election of ten directors, ratification of Ernst & Young LLP as the independent accounting firm for 2025, and approval of amendments to the 2011 Long-Term Incentive Plan, the 2011 Performance Incentive Award Plan, and the 2008 Employee Stock Purchase Plan.
• The board recommends voting for all director nominees, ratification of the accounting firm, and approval of the incentive plan amendments.
• A shareholder proposal regarding transparency in political spending is also on the agenda, with the board recommending a vote against it.
• The company's financial performance for 2024 includes net sales of $22.595 billion, net earnings of $2.993 billion, and adjusted net earnings of $4.700 billion.
• The company paid dividends of $3.20 per share of common stock in 2024.
• The proxy statement includes details on executive compensation, corporate governance practices, and stock ownership.
• The company's three-year average equity run rate is 0.5% and overhang is 8.7%.

Sentiment

Score: 7

Explanation: The document presents a balanced view of Stryker's performance and future plans. While there are some negative aspects, such as a decrease in net earnings, the overall tone is positive due to the proposed amendments to incentive plans and the company's commitment to corporate governance.

Positives

• The company is proposing amendments to its equity incentive plans to continue attracting and retaining talented employees and directors.
• Stryker's financial performance in 2024 showed growth in net sales and adjusted net earnings.
• The company maintains a recoupment policy for cash and equity incentive awards in the event of financial restatements or misconduct.
• The company has stock ownership guidelines for senior executives and non-employee directors to align their interests with shareholders.
• The company's executive compensation program is designed to align with organizational and individual performance and shareholder interests.

Negatives

• Net earnings decreased by 5.4% from 2023 to 2024.
• Earnings before income taxes decreased by 4.9% from 2023 to 2024.
• A shareholder proposal regarding transparency in political spending was submitted, indicating some shareholder concern in this area.

Risks

• The proxy statement includes a cautionary note regarding forward-looking statements, highlighting the risks, uncertainties, and assumptions that could cause actual results to differ materially.
• The company faces risks related to financial, legal/compliance, cybersecurity, and operational/strategic aspects of its business.
• The company's future equity grant practices could impact the duration of the share reserve under the 2011 Plan.

Future Outlook

The proxy statement contains forward-looking statements based on current projections about operations, industry conditions, financial condition, and liquidity, which are subject to risks and uncertainties.

Management Comments

• Management and the Board believe that our prior equity incentive plans have been helpful in attracting and retaining skilled personnel.
• The members of the Audit Committee and the Board believe that the continued retention of Ernst & Young LLP is in the best interest of the Company and our shareholders.
• Our Board recognizes that approval of this proposal may benefit our current directors and their successors.

Industry Context

The document references a comparison group of medical technology and related companies used for benchmarking executive compensation, indicating Stryker's awareness of competitive practices within its industry.

Comparison to Industry Standards

• The comparison group companies used in the 2023 benchmarking study were: Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Agilent Technologies, Inc., Danaher Corporation, Quest Diagnostics Incorporated, Amgen Inc., Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., Baxter International Inc., Gilead Sciences, Inc., Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Laboratory Corporation of America Holdings, Viatris Inc., Biogen Inc., Zimmer Biomet Holdings, Inc.
• The comparison group that was used in the 2024 study included the same companies that were used in the 2023 study except that Agilent Technologies, Inc. was removed from the group due to size considerations and GE HealthCare Technologies Inc. was added to the group as a result of it becoming a public company in the medical technology industry.

Management Changes

Corporate Governance

Related Party Transactions

• The Board considered that the Company spent $630,000 in 2024 on functions and meetings held at hotel, restaurant and entertainment properties in Kalamazoo, Michigan (principally the Radisson Plaza Hotel) that are owned by Greenleaf Hospitality and that Stryker also reimbursed employees for hotel, restaurant and other expenses incurred by them at such properties while they were in Kalamazoo for business meetings.
• The Board considered that the Company contracts for consulting services from Bain & Company, where Mr. Maceda is a partner and serves as Chair. The agreements governing these consulting services are entered into in the ordinary course of business and payments from the Company to Bain & Company in 2024 did not exceed 2% of Bain & Companys consolidated gross revenue.

Stakeholder Impact

• Shareholders will have the opportunity to vote on key decisions affecting the company's direction and governance.
• Employees may be affected by changes to the incentive plans and stock purchase plan.
• The company's performance and governance practices can impact its reputation and relationships with customers, suppliers, and creditors.

Next Steps

• Shareholders will vote on the proposals at the annual meeting on May 8, 2025.
• The Board and Compensation and Human Capital Committee will review the results of the advisory vote on executive compensation and take them into account in future determinations.
• The company will continue to monitor and assess risks related to compensation programs and corporate governance practices.

Key Dates

Keywords

proxy statement, shareholder meeting, executive compensation, corporate governance, director elections, incentive plans, financial performance, stock ownership, Stryker